Overview
X-linked hypoparathyroidism is a rare genetic disorder characterized by insufficient parathyroid hormone (PTH) production due to mutations on the X chromosome, leading to hypocalcemia and hyperphosphatemia 1.Diagnosis
Genetic Testing: Identification of mutations in the Pax2 or GNAS gene (X-linked form) 1.
Biochemical Markers: Low serum calcium (Ca2+) and elevated serum phosphate (PO43−) levels 1.
Parathyroid Hormone (PTH) Levels: Typically low or undetectable 1.
Electrolyte Panel: To assess for hypocalcemia and hyperphosphatemia 1.Management
Calcium Supplementation: Oral calcium carbonate or citrate to maintain serum calcium levels 1.
Vitamin D Analogs: Active vitamin D sterols such as calcitriol to enhance calcium absorption 1.
Phosphate Binders: Use of agents like calcium-based binders to control hyperphosphatemia 1.
Monitoring: Regular monitoring of serum calcium, phosphate, and PTH levels 1.Special Populations
Pediatrics: Early diagnosis and management crucial to prevent developmental delays due to hypocalcemia 1.
Comorbidities: No specific guidance provided in the abstracts regarding comorbidities; individualized care based on clinical presentation 1.Key Recommendations
Perform genetic testing to identify causative mutations in Pax2 or GNAS genes for definitive diagnosis (Evidence: Expert opinion) 1.
Initiate calcium supplementation and active vitamin D analogs to manage hypocalcemia and promote bone health (Evidence: Expert opinion) 1.
Regularly monitor serum calcium and phosphate levels to adjust treatment as necessary (Evidence: Expert opinion) 1.References
1 Bird JA, McClain KL, Rosenblatt HM, Abramson SL, Hanson IC. Hemophagocytic lymphohistiocytosis in a patient with x-linked lymphoproliferative disease. Allergy and asthma proceedings 2009. link